DENVER: The US biotech firm Inovio reported preliminary but encouraging results Tuesday (Wednesday in Manila) from tests of an experimental coronavirus vaccine.

Administered to 40 volunteers, it triggered an immune system response in 94 percent of those who completed the so-called phase one clinical trial, meaning they received two injections, four weeks apart.